Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company`s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obese patients without permanently cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
Website: reshapelifesciences.com



Growth: Bad revenue growth rate -25.0%, there is slowdown compared to average historical growth rates 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -600.0%. On average the margin is decreasing steadily. Gross margin is high, +75.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 33% of quarters (showing a gain of -$5.70 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -24 463.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 19.6% higher than minimum and 100.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -28.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: RSLS
Share price, USD:  (-0.4%)0.1812
year average price 1.0136  


year start price 2.8000 2023-03-30

max close price 3.1300 2023-04-17

min close price 0.1515 2024-02-26

current price 0.1812 2024-03-28
Common stocks: 451 181

Dividend Yield:  0.0%
Last revenue growth (y/y):  -25.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  ---
Historical growth of EBITDA:  0.0%
EV / Sales: -0.5x
Margin (EBITDA LTM / Revenue): -600.0%
Fundamental value created in LTM:
Market Cap ($m): 0
Net Debt ($m): -6
EV (Enterprise Value): -6
Price to Book: 0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-12-13InvestorPlace

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

2023-12-13Proactive Investors

ReShape Lifesciences stock soars as obesity treatment gets FDA greenlight

2023-11-06GlobeNewsWire

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

2023-10-25InvestorPlace

Why Is Reshape Lifesciences (RSLS) Stock Up 59% Today?

2023-08-07Seeking Alpha

ReShape Lifesciences Inc. (RSLS) Q2 2023 Earnings Call Transcript

2023-05-11GlobeNewsWire

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update

2023-04-29Seeking Alpha

ReShape Lifesciences Inc. (RSLS) Q4 2022 Earnings Call Transcript

2023-04-27GlobeNewsWire

ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-09 2023-08-07 2023-05-15 2023-04-17 2022-11-14 2022-08-19
acceptedDate 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 2M 2M 2M 3M 3M 3M
costOfRevenue 867 000 1M 1M 2M 697 000 1M
grossProfit 1M 1M 1M 2M 2M 2M
grossProfitRatio 0.598 0.530 0.535 0.514 0.751 0.651
researchAndDevelopmentExpenses 542 000 581 000 453 000 441 000 588 000 761 000
generalAndAdministrativeExpenses 2M 2M 4M 4M 4M 5M
sellingAndMarketingExpenses 2M 2M 2M 2M 3M 5M
sellingGeneralAndAdministrativeExpenses 4M 5M 6M 6M 6M 10M
otherExpenses 0 6000.000 2000.000 2000.000 0 0
operatingExpenses 4M 5M 7M 6M 7M 11M
costAndExpenses 5M 6M 8M 8M 8M 12M
interestIncome 5000.000 9000.000 0 -46 000 31 000 14 000
interestExpense 0 0 5000.000 4M 31 000 14 000
depreciationAndAmortization 50 000 49 000 2000.000 -7M 543 000 545 000
ebitda -3M -4M -6M -12M 3M -9M
ebitdaratio -1.440 -1.981 -2.461 -3.851 0.998 -3.115
operatingIncome -3M -4M -6M -5M 2M -9M
operatingIncomeRatio -1.440 -1.764 -2.462 -1.513 0.804 -3.242
totalOtherIncomeExpensesNet -428 000 511 000 3M -12M -14M -191 000
incomeBeforeTax -4M -3M -3M -16M -12M -10M
incomeBeforeTaxRatio -1.639 -1.548 -1.158 -5.299 -4.351 -3.308
incomeTaxExpense 3000.000 4000.000 14 000 131 000 -363 000 9000.000
netIncome -4M -3M -3M -17M -12M -10M
netIncomeRatio -1.640 -1.550 -1.164 -5.341 -4.221 -3.311
eps -1.020 -1.080 -1.560 -39.140 -26.180 -24.392
epsdiluted -1.020 -1.080 -1.560 -39.140 -26.180 -24.392
weightedAverageShsOut 3M 3M 2M 424 390 451 181 392 594
weightedAverageShsOutDil 3M 3M 2M 424 390 451 181 392 594
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-09 2023-08-07 2023-05-15 2023-04-17 2022-11-14 2022-08-19
acceptedDate 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 1M 5M 9M 4M 6M 11M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 1M 5M 9M 4M 6M 11M
netReceivables 2M 2M 2M 2M 2M 2M
inventory 3M 3M 3M 4M 4M 4M
otherCurrentAssets 94 000 112 000 530 000 84 000 157 000 1M
totalCurrentAssets 7M 11M 15M 10M 14M 19M
propertyPlantEquipmentNet 344 000 956 000 758 000 869 000 1M 1M
goodwill 0 0 0 0 0 0
intangibleAssets 0 238 000 249 000 260 000 13M 20M
goodwillAndIntangibleAssets 0 238 000 249 000 260 000 13M 20M
longTermInvestments 0 0 0 0 0 0
taxAssets 55 000 57 000 57 000 56 000 0 0
otherNonCurrentAssets 29 000 57 000 57 000 46 000 1M 1M
totalNonCurrentAssets 428 000 1M 1M 1M 15M 22M
otherAssets 0 0 0 0 0 0
totalAssets 8M 12M 16M 11M 28M 42M
accountPayables 1M 2M 2M 2M 2M 3M
shortTermDebt 110 000 109 000 86 000 171 000 255 000 338 000
taxPayables 54 000 68 000 122 000 119 000 120 000 190 000
deferredRevenue 657 000 459 000 573 000 510 000 644 000 605 000
otherCurrentLiabilities 2M 2M 5M 5M 5M 6M
totalCurrentLiabilities 4M 4M 8M 7M 8M 9M
longTermDebt 175 000 198 000 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 367 000
otherNonCurrentLiabilities 100 000 512 000 992 000 3M -3M 5000.000
totalNonCurrentLiabilities 275 000 710 000 992 000 3M 3M 372 000
otherLiabilities 0 0 0 -3M -3M 0
capitalLeaseObligations 285 000 307 000 86 000 171 000 255 000 338 000
totalLiabilities 5M 5M 9M 7M 8M 10M
preferredStock 100 000 512 000 0 0 0 0
commonStock 3000.000 3000.000 3000.000 1000.000 23 000 20 000
retainedEarnings -634M -630M -627M -624M -606M -595M
accumulatedOtherComprehensiveIncomeLoss -94 000 -95 000 -93 000 -88 000 -68 000 -72 000
othertotalStockholdersEquity 637M 637M 635M 628M 627M 627M
totalStockholdersEquity 3M 7M 8M 4M 21M 32M
totalEquity 3M 7M 8M 4M 21M 32M
totalLiabilitiesAndStockholdersEquity 8M 12M 16M 11M 28M 42M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 8M 12M 16M 11M 28M 42M
totalInvestments 0 0 0 0 0 0
totalDebt 285 000 307 000 86 000 171 000 255 000 338 000
netDebt -1M -4M -9M -4M -6M -11M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-09 2023-08-07 2023-05-15 2023-04-17 2022-11-14 2022-08-19
acceptedDate 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -4M -3M -3M -17M -12M -10M
depreciationAndAmortization 50 000 49 000 48 000 515 000 543 000 545 000
deferredIncomeTax 2000.000 4000.000 -1000.000 132 000 -367 000 -1000.000
stockBasedCompensation 216 000 218 000 222 000 130 000 387 000 823 000
changeInWorkingCapital -218 000 -3M -47 000 604 000 -1M 1M
accountsReceivables -482 000 39 000 21 000 678 000 0 0
inventory 31 000 168 000 108 000 130 000 35 000 -279 000
accountsPayables 69 000 -3M 344 000 0 0 0
otherWorkingCapital 164 000 -138 000 -520 000 -204 000 -1M 79 000
otherNonCashItems 704 000 -332 000 -3M 12M 7M 304 000
netCashProvidedByOperatingActivities -3M -7M -5M -3M -5M -6M
investmentsInPropertyPlantAndEquipment 0 -36 000 -7000.000 -79 000 -33 000 0
acquisitionsNet 0 33 000 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 10M 0 0 0
otherInvestingActivites 0 0 -10M 0 0 18 000
netCashUsedForInvestingActivites 0 -3000.000 -7000.000 -79 000 -33 000 18 000
debtRepayment 0 0 0 0 0 0
commonStockIssued -338 000 2M 10M 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 0 638 000 3000.000 2M
netCashUsedProvidedByFinancingActivities -338 000 2M 10M 638 000 3000.000 2M
effectOfForexChangesOnCash 0 -1000.000 -5000.000 -20 000 4000.000 -1000.000
netChangeInCash -3M -4M 5M -2M -5M -4M
cashAtEndOfPeriod 2M 5M 9M 4M 6M 12M
cashAtBeginningOfPeriod 5M 9M 4M 6M 12M 15M
operatingCashFlow -3M -7M -5M -3M -5M -6M
capitalExpenditure 0 -36 000 -7000.000 -79 000 -33 000 -12 000
freeCashFlow -3M -7M -5M -3M -5M -6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-10 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-15 ET (fiscal 2023 q1)
2022 q4
2023-04-29 ET (fiscal 2022 q4)
2022 q3
2022-11-14 ET (fiscal 2022 q3)
2022 q2
2022-08-15 ET (fiscal 2022 q2)
2022 q1
2022-05-23 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-24 13:31 ET
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
2023-12-21 12:00 ET
ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex
2023-12-20 13:31 ET
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
2023-12-12 21:05 ET
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
2023-11-21 13:06 ET
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
2023-11-08 21:05 ET
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
2023-11-06 13:31 ET
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
2023-09-29 16:30 ET
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
2023-09-22 12:31 ET
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
2023-09-21 12:31 ET
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
2023-09-19 12:31 ET
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
2023-09-14 12:31 ET
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
2023-08-07 20:05 ET
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
2023-08-03 20:05 ET
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
2023-06-29 12:31 ET
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
2023-06-28 12:31 ET
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
2023-06-26 20:05 ET
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
2023-06-14 12:31 ET
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
2023-05-15 20:05 ET
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
2023-05-11 12:30 ET
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
2023-04-27 12:30 ET
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
2023-04-25 20:05 ET
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
2023-04-20 12:30 ET
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
2023-04-11 12:30 ET
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
2023-03-29 01:50 ET
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
2023-03-23 12:30 ET
ReShape Lifesciences Announces Formation of International Scientific Advisory Board
2023-03-22 12:30 ET
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
2023-03-15 12:30 ET
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
2023-02-08 17:07 ET
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
2023-02-06 13:30 ET
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
2022-12-22 13:30 ET
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
2022-11-14 12:30 ET
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-08 14:28 ET
ReShape Lifesciences Announces $750,000 Registered Direct Offering
2022-11-07 18:22 ET
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
2022-11-03 12:30 ET
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
2022-11-02 13:11 ET
ReShape Lifesciences to Present at the Q4 Investor Summit
2022-10-31 12:30 ET
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
2022-10-25 12:30 ET
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
2022-10-20 12:30 ET
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
2022-09-22 12:30 ET
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
2022-09-14 12:30 ET
ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference
2022-08-23 12:30 ET
ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations
2022-08-15 20:05 ET
ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-08-10 20:29 ET
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
2022-08-10 16:05 ET
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric Procedures
2022-07-27 20:05 ET
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
2022-06-17 12:30 ET
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
2022-05-26 12:30 ET
ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and Wellness Through reshapecare™
2022-05-23 12:00 ET
ReShape Lifesciences™ Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-19 12:30 ET
ReShape Lifesciences™ Announces Vernon Vincent to be Recognized as the Distinguished Industry Partner at the ASMBS 2022 LEAD Gala and Awards
2022-05-16 12:30 ET
ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
2022-04-26 12:30 ET
ReShape Lifesciences to Present at the Q2 Investor Summit
2022-03-28 20:05 ET
ReShape Lifesciences™ Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update
2022-03-24 12:30 ET
ReShape Lifesciences™ Experiences Continued Momentum of Direct-to-Consumer Marketing Campaign for the Lap-Band®
2022-03-17 13:07 ET
ReShape Lifesciences™ to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
2022-03-09 13:30 ET
ReShape Lifesciences to Participate in Investor Conferences in March
2022-01-18 13:30 ET
ReShape Lifesciences™ to Participate in the American Society for Metabolic and Bariatric Surgery’s (ASMBS) Leadership Academy and re-UNITED Meeting January 19-22, 2022 in Las Vegas
2022-01-13 13:30 ET
ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations
2021-12-09 13:35 ET
ReShape Lifesciences to Webcast Live at Life Sciences Investor Forum on December 16th
2021-11-16 13:30 ET
ReShape Lifesciences Witnesses Great Success with Direct-to-Consumer Marketing Campaign
2021-11-11 13:30 ET
ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results
2021-11-08 13:30 ET
ReShape Lifesciences to Report Third Quarter 2021 Financial and Operational Results on Thursday, November 11, 2021
2021-11-04 12:30 ET
ReShape Lifesciences™ to Launch Line of ProCare Health® Supplements to Meet Consumers’ Nutritional Needs
2021-10-19 12:30 ET
ReShape Lifesciences to Present at Dawson James 6th Annual Small Cap Growth Conference
2021-10-12 12:00 ET
ReShape Launches National Advertising Campaign for Flagship Product, Lap-Band®
2021-09-23 12:00 ET
ReShape Lifesciences™ Featured in BioTuesdays
2021-09-13 12:00 ET
ReShape Lifesciences™ to Host Exhibit at Bariatric Summit
2021-09-09 12:30 ET
ReShape Lifesciences™ to Present at Oppenheimer Fall Healthcare Life Sciences and Med Tech Summit on September 20, 2021
2021-08-31 12:00 ET
ReShape Lifesciences™ Appoints Al Diaz as Vice President of Operations and Research and Development
2021-08-16 12:00 ET
ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update
2021-08-05 12:00 ET
ReShape Lifesciences Reports Preliminary Unaudited Second Quarter 2021 Financial Results and Provides Business Update
2021-08-03 12:00 ET
ReShape Lifesciences(TM) CEO Bart Bandy Featured on the Big Biz Show
2021-07-29 12:30 ET
ReShape Lifesciences to Report Second Quarter 2021 Financial and Operational Results on Thursday, August 5, 2021
2021-07-13 12:30 ET
ReShape Lifesciences(TM) Launches Online Consumer Marketplace Offering Products Supporting Four Key Dimensions of Wellness: Nutrition, Exercise, Sleep and Stress
2021-07-07 12:30 ET
ReShape Lifesciences Moves Lap-Band Manufacturing to United States
2021-07-01 12:30 ET
ReShape Lifesciences Sees Lap-Band Growth as COVID-19 Pandemic Heightens Obesity Crisis
2021-06-30 12:30 ET
ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders
2021-06-29 13:27 ET
ReShape Lifesciences Enters into Warrant Exercise Transaction for $46.2 Million in Gross Proceeds
2021-06-17 12:45 ET
ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market
2021-06-16 11:30 ET
ReShape Lifesciences Completes Merger with Obalon Therapeutics
2021-06-15 16:05 ET
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger
2021-06-08 11:30 ET
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger
2021-05-21 11:30 ET
Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences
2021-05-18 11:30 ET
Obalon Therapeutics Stockholders Special Meeting Adjourned to May 25, 2021
2021-05-17 20:05 ET
ReShape Lifesciences Announces First Quarter 2021 Financial and Operational Results
2021-05-12 12:40 ET
Obalon Announces First Quarter 2021 Financial Results
2021-05-12 11:30 ET
Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc
2021-03-13 00:12 ET
Obalon Announces Fourth Quarter and Full Year 2020 Financial Results
2021-03-10 21:30 ET
ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results
2021-03-08 13:00 ET
Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021
2021-01-20 13:45 ET
ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering
2020-11-12 21:30 ET
ReShape Lifesciences Announces Third Quarter 2020 Financial and Operational Results
2020-11-10 13:00 ET
ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020
2020-11-06 21:45 ET
Obalon Announces Third Quarter 2020 Financial Results
2020-09-15 12:00 ET
First Twenty-five Healthcare Professionals Enrolled in ReShapeCare™, a Reimbursable, Evidence-based Virtual Weight Management Program
2020-09-10 12:00 ET
ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device
2020-08-13 20:30 ET
ReShape Lifesciences Announces Second Quarter 2020 Financial and Operational Results
2020-08-13 11:00 ET
Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System
2020-08-11 12:00 ET
ReShape Lifesciences to Report Second Quarter 2020 Financial and Operational Results on Thursday, August 13, 2020
2020-07-30 10:38 ET
Obalon Announces Second Quarter 2020 Financial Results
2020-07-21 12:00 ET
ReShape Lifesciences Recognizes National Parents' Day Offering New Resources for Women Considering Weight-Loss and Parenthood
2020-07-13 12:00 ET
ReShape Lifesciences' Weight-Loss Portfolio Aligned with CDC's COVID-19 Updates
2020-06-22 12:00 ET
ReShape Lifesciences and inHealth Lifestyle Therapeutics Launch ReShapeCare(TM) Virtual Health Coaching for Patients with Obesity
2020-06-19 10:15 ET
Obalon Announces First Quarter 2020 Financial Results and Business Update
2020-05-14 20:05 ET
ReShape Lifesciences Announces First Quarter 2020 Financial and Operational Results
2020-05-11 12:30 ET
Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment
2020-05-08 12:00 ET
William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director
2020-04-28 13:00 ET
Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons
2020-03-26 20:05 ET
ReShape Lifesciences Announces Fourth Quarter and Full Year 2019 Financial Results
2020-03-25 12:30 ET
Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives
2020-03-23 12:00 ET
ReShape Lifesciences to Host Fourth Quarter and Full Year 2019 Conference Call on March 26, 2020
2020-03-17 21:21 ET
Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic
2020-02-27 12:31 ET
Obalon Announces Fourth Quarter and Full Year 2019 Financial Results
2020-02-20 13:15 ET
Obalon Announces Opening of Second Retail Treatment Center in Orange County, CA
2020-02-13 14:00 ET
Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time
2020-02-07 21:15 ET
Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capital Fund
2019-12-18 13:30 ET
Obalon Enters into a Distribution Agreement for Qatar
2019-11-14 14:00 ET
Obalon To Present at Two Upcoming Institutional Investor Conferences
2019-11-11 17:50 ET
ReShape Lifesciences Announces 1-for-120 Reverse Stock Split
2019-11-08 12:15 ET
Obalon Announces Third Quarter 2019 Financial Results
2019-11-07 22:30 ET
ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019
2019-11-05 13:00 ET
ReShape Lifesciences Announces Strategic Marketing Partnership for LAP-BAND(R)
2019-11-05 10:15 ET
Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019
2019-10-31 11:15 ET
Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time
2019-10-30 12:00 ET
ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer
2019-10-24 12:15 ET
Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer
2019-10-22 12:15 ET
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
2019-10-17 12:00 ET
ReShape Lifesciences Announces Attendance and Presentation at Obesity Week 2019
2019-10-03 13:00 ET
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement
2019-09-28 16:42 ET
Obalon (OBLN) Alert: Johnson Fistel Announces Shareholder Class Action Against Obalon Therapeutics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?
2019-05-30 13:31 ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Dollar General, Eltek, or Obalon Therapeutics?
2019-05-23 13:31 ET
Thinking about buying stock in Avon Products, Genocea Biosciences, L Brands, Netshoes, or Obalon Therapeutics?

SEC forms

Show financial reports only

SEC form 10
2023-11-09 00:00 ET
ReShape Lifesciences reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
ReShape Lifesciences reported for 2023 q3
SEC form 8
2023-08-07 00:00 ET
ReShape Lifesciences reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
ReShape Lifesciences reported for 2023 q2
SEC form 8
2023-05-16 00:00 ET
ReShape Lifesciences reported for 2023 q1
SEC form 6
2023-05-15 17:40 ET
ReShape Lifesciences reported for 2023 q1
SEC form 10
2023-05-15 16:51 ET
ReShape Lifesciences reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
ReShape Lifesciences reported for 2023 q1
SEC form 6
2023-04-26 16:06 ET
ReShape Lifesciences published news for 2023 q1
SEC form 10
2023-04-17 16:55 ET
ReShape Lifesciences reported for 2022 q4
SEC form 10
2023-04-17 00:00 ET
ReShape Lifesciences reported for 2022 q4
SEC form 6
2023-04-13 17:24 ET
ReShape Lifesciences published news for 2023 q1
SEC form 6
2023-04-03 17:11 ET
ReShape Lifesciences published news for 2023 q1
SEC form 6
2023-03-21 16:18 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2023-02-10 16:05 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2023-01-27 06:06 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2022-12-28 16:18 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-12-20 17:30 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-11-14 17:23 ET
ReShape Lifesciences reported for 2022 q3
SEC form 6
2022-11-14 16:54 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-11-14 06:19 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
ReShape Lifesciences reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
ReShape Lifesciences reported for 2022 q3
SEC form 6
2022-11-10 16:55 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-10-31 16:02 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-08-19 17:17 ET
ReShape Lifesciences reported for 2022 q2
SEC form 10
2022-08-19 00:00 ET
ReShape Lifesciences reported for 2022 q2
SEC form 8
2022-08-16 00:00 ET
ReShape Lifesciences reported for 2022 q2
SEC form 6
2022-08-15 20:07 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-08-15 18:31 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-08-02 16:09 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-07-25 16:05 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-07-21 16:05 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-06-23 16:38 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-05-23 15:13 ET
ReShape Lifesciences reported for 2022 q1
SEC form 6
2022-05-23 10:33 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-05-23 00:00 ET
ReShape Lifesciences reported for 2022 q1
SEC form 8
2022-05-23 00:00 ET
ReShape Lifesciences reported for 2022 q1
SEC form 6
2022-05-13 17:15 ET
ReShape Lifesciences published news for 2022 q1
SEC form 6
2022-04-14 17:12 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-04-08 17:10 ET
ReShape Lifesciences published news for 2021 q4
SEC form 10
2022-04-08 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-31 20:23 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-28 17:30 ET
ReShape Lifesciences published news for 2021 q4
SEC form 8
2022-03-28 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-21 19:01 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-17 08:35 ET
ReShape Lifesciences published news for 2021 q4
SEC form 8
2022-03-17 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 10
2021-11-12 15:43 ET
ReShape Lifesciences published news for 2021 q3
SEC form 6
2021-11-12 15:38 ET
ReShape Lifesciences published news for 2021 q3
SEC form 8
2021-11-12 00:00 ET
ReShape Lifesciences published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
ReShape Lifesciences published news for 2021 q3
SEC form 10
2021-08-16 11:36 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-08-16 11:18 ET
ReShape Lifesciences published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
ReShape Lifesciences published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-07-19 08:01 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-07-02 16:05 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-06-15 17:11 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-06-15 12:20 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-26 06:02 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-21 09:02 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-18 16:07 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-13 16:03 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-05-12 08:32 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-12 08:30 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-04 16:03 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-03-12 16:12 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-03-12 16:10 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-02-10 16:05 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-01-22 16:15 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-01-20 08:33 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2020-12-18 06:06 ET
ReShape Lifesciences published news for 2020 q3
SEC form 6
2020-12-15 16:15 ET
ReShape Lifesciences published news for 2020 q3
SEC form 6
2020-11-06 16:46 ET
ReShape Lifesciences published news for 2020 q3
SEC form 10
2020-11-06 16:31 ET
ReShape Lifesciences published news for 2020 q3